glp-1 news november 6 2025 🚨 Breaking in Obesity Care! 🚨 President Trump just announced major deals with Eli Lilly and Novo Nordisk — the makers of Mounjaro, Zepbound, Wegovy, and Ozempic — to slash weight When the Breakthrough Obesity G-Agonist

Some insurance plans may require prior authorization or additional documentation from the healthcare provider to approve Semaglutide GLP-1 treatment

General anesthesia triggered gene expression changes consistent with astrocytes being in a low-activity environment, but additionally caused induction of a reactive profile, with transcriptional changes enriched in those triggered by stroke, neuroinflammation, and A/tau pathology

TLR2 promotes traumatic deep venous thrombosis of the lower extremity following femoral fracture by activating the NF-B/COX-2 signaling pathway in rats

Tirzepatide : Approved in 2022 (Mounjaro) and 2024 (Zepbound), its NCE exclusivity runs to May 2027, delaying generic filings until 2026